Abdominal Aortic Aneurysm Epidemiology
- An abdominal aortic aneurysm is an enlargement or bulging in the section of the aorta
- (the largest artery in the body, originating from the heart's left ventricle) that passes through the abdomen. It typically does not cause symptoms, but some individuals may experience intense pain in their lower back or a pulsating sensation in their abdomen.
- Abdominal aortic aneurysms often do not cause noticeable symptoms, so healthcare providers usually detect unruptured aneurysms during tests performed for other medical reasons. If a healthcare provider suspects aneurysm based on test results or other signs, they might order imaging tests such as an abdominal duplex ultrasound or a computed tomography angiogram (CTA).
- A one-time abdominal ultrasound is recommended for men aged 65 to 75 who have ever smoked.
- The prevalence of abdominal aortic aneurysm in females is significantly lower, ranging from 0.6% to 1.4%. Additionally, the frequency of abdominal aortic aneurysm rupture in the United Kingdom has been reported as 13 cases per 100,000 individuals.
- In Japan, the prevalence of symptomatic abdominal aortic aneurysm among the old age group (>50) was 12%. Abdominal aortic aneurysm is more prevalent in males in Japan as compared to females.
- The frequency of abdominal aortic aneurysm begins to rise after the age of 60, reaching its highest risk level during the seventh and eighth decades of life.
DelveInsight’s “Abdominal aortic aneurysm Epidemiology Forecast – 2034” report delivers an in-depth understanding of Abdominal aortic aneurysm, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The table given below further depicts the key segments provided in the report:
Abdominal aortic aneurysm: Disease Understanding
Abdominal aortic aneurysm Overview, and Diagnosis
An abdominal aortic aneurysm (AAA) is a condition where a section of the aorta, the body's main artery located in the abdomen, becomes abnormally enlarged or bulges outward. It is characterized by a permanent, localized dilation of the vessel, where the diameter increases by at least 150% compared to the normal size of the adjacent artery which may be discovered either in the screening of any other disease or when a rupture occurs.
Risk factors for abdominal aortic aneurysms (AAAs) include atherosclerosis (the most common), smoking, older age, male sex, a family history of AAA, hypertension, hypercholesterolemia, and a previous history of aortic dissection. Other contributing causes include cystic medial necrosis, syphilis, human immunodeficiency virus (HIV), and connective tissue disorders such as Ehlers-Danlos syndrome, Marfan syndrome, and Loeys-Dietz syndrome.
Aneurysms often develop gradually over many years without causing symptoms. However, symptoms can emerge suddenly if the aneurysm grows quickly, ruptures, or leaks blood within the vessel wall (aortic dissection). Symptoms of rupture include:
Intense, sudden, or persistent pain in the abdomen or back, which may radiate to the groin, buttocks, or legs.
- Fainting or loss of consciousness.
- Cool, clammy skin.
- Dizziness.
- Nausea and vomiting.
- Rapid heart rate.
- Signs of shock.
The Abdominal aortic aneurysm report provides an overview of abdominal aortic aneurysm pathophysiology, diagnostic approaches, and detailed diagnostic algorithm along with a real-world scenario of a patient’s journey beginning from the first symptom, and the time taken for diagnosis.
For More Insights into the Report @ Abdominal Aortic Aneurysm Treatment Market
Abdominal aortic aneurysm Epidemiology
The abdominal aortic aneurysm epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases, total diagnosed prevalent cases, gender-specific cases, and age-specific cases of Abdominal aortic aneurysm in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2020 to 2034.
- According to a study, the prevalence of abdominal aortic aneurysm in screening studies ranges from 3% to 8%, with males being the most affected group.
- The prevalence of asymptomatic abdominal aortic aneurysm has been reported as 8.2% in the United Kingdom and 8.8% in Italy (only in males).
- The reported frequency of abdominal aortic aneurysm rupture in the US is approximately 4.4 cases per 100,000 individuals.
- In Spain, the prevalence of abdominal aortic aneurysm among men aged 65–74 years was found to be 2.3%.
- The condition primarily affects older individuals, with the average age of onset occurring between 55 and 65 years, while in females, it typically develops 5 to 8 years later.
KOL Views
To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.
DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as the University of Michigan; University of Florida, University of Kentucky, and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.
More Insights into the Report @ Abdominal Aortic Aneurysm Pipeline Drugs
Scope of the Abdominal aortic aneurysm Report
- The report covers a segment of key events, an executive summary, and a descriptive overview of abdominal aortic aneurysm, explaining its causes, signs and symptoms, pathogenesis, and current diagnosis methods.
- Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
- A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.
Abdominal aortic aneurysm Report Insights
- Abdominal aortic aneurysm Patient Population
- Country-wise Epidemiology Distribution
Abdominal aortic aneurysm Report Key Strengths
- Ten-year Forecast
- The 7MM Coverage
- Abdominal aortic aneurysm Epidemiology Segmentation
Abdominal aortic aneurysm Report Assessment
- Abdominal aortic aneurysm Epidemiology Segmentation
- Current Diagnostic Practices
FAQs
Abdominal aortic aneurysm Epidemiology Insights
- What are the disease risks, burdens, and unmet needs of abdominal aortic aneurysm? What will be the growth opportunities across the 7MM concerning the patient population pertaining to abdominal aortic aneurysm?
- What is the historical and forecasted Abdominal aortic aneurysm patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
- What is the diagnostic pattern of abdominal aortic aneurysm?
- Which clinical factors will affect abdominal aortic aneurysm?
- Which factors will affect the increase in the diagnosis of abdominal aortic aneurysm?
Reasons to buy Abdominal aortic aneurysm Epidemioloy Reports
- Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand the change in Abdominal aortic aneurysm cases in varying geographies over the coming years.
- A detailed overview of total prevalent cases of abdominal aortic aneurysm, diagnosed prevalent cases of abdominal aortic aneurysm, gender-specific cases of abdominal aortic aneurysm, and age-specific cases of Abdominal aortic aneurysm is included.
- To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Stay updated with us for Recent Articles @ New DelveInsight Blogs
Table of Contents
1 Key Insights
2 Report Introduction
3 Abdominal aortic aneurysm Patient Overview at a Glance
3.1 Patient Share Distribution (%) in the 7MM in 2024
3.2 Patient Share Distribution (%) in the 7MM in 2034
4 Executive Summary of Abdominal aortic aneurysm
5 Key Events
6 Epidemiology Forecast Methodology
7 Disease Background and Overview
7.1 Introduction
7.2 Signs and Symptoms
7.3 Causes
7.4 Diagnosis and Differential Diagnosis
7.4.1 Diagnostic Algorithm
7.4.2 Differential Diagnosis
7.4.3 Diagnostic Guidelines
8 Abdominal aortic aneurysm Epidemiology and Patient Population
8.1 Key Findings
8.2 Assumptions and Rationale
8.3 Total Diagnosed Prevalent Cases of Abdominal aortic aneurysm in the 7MM
8.4 The United States
8.4.1 Total Prevalent Cases Of Abdominal aortic aneurysm in the United States
8.4.2 Total Diagnosed Prevalent Cases Of Abdominal aortic aneurysm in the United States
8.4.3 Gender-specific Cases Of Abdominal aortic aneurysm in the United States
8.4.4 Age-specific Cases Of Abdominal aortic aneurysm in the United States
8.5 EU4 and the UK
8.5.1 Total Prevalent Cases Of Abdominal aortic aneurysm in EU4 and the UK
8.5.2 Total Diagnosed Prevalent Cases Of Abdominal aortic aneurysm in EU4 and the UK
8.5.3 Gender-specific Cases Of Abdominal aortic aneurysm in EU4 and the UK
8.5.4 Age-specific Cases Of Abdominal aortic aneurysm in EU4 and the UK
8.6 Japan
8.6.1 Total Prevalent Cases Of Abdominal aortic aneurysm in Japan
8.6.2 Total Diagnosed Prevalent Cases Of Abdominal aortic aneurysm in Japan
8.6.3 Gender-specific Cases Of Abdominal aortic aneurysm in Japan
8.6.4 Age-specific Cases Of Abdominal aortic aneurysm in Japan
9 Appendix
9.1 Acronyms and Abbreviations
9.2 Bibliography
9.3 Report Methodology
10 DelveInsight Capabilities
11 Disclaimer
12 About DelveInsight
List of Tables:
List of Tables
Table 1: Summary of AAA Epidemiology (2021-2034)
Table 2: Abdominal aortic aneurysm endovascular devices commonly used in the United States
Table 3: Assessment based on the stage
Table 4: Total Prevalent Patient Population of AAA in 7MM (2021-2034)
Table 5: Total Gender-specific Prevalent Population of AAA (2021-2034)
Table 6: Total Size-Specific Prevalence of AAA (2021-2034)
Table 7: Total Treatable Population of AAA (2021-2034)
Table 8: Total Treatable Population by Type of Treatment of AAA (2021-2034)
Table 9: Total Diagnosed Prevalence of AAA (2021-2034)
Table 10: Total Diagnosed Gender-Specific Prevalence of AAA (2021-2034)
Table 11: Size-Specific Prevalence of AAA (2021-2034)
Table 12: Total Treatable Population of AAA (2021-2034)
Table 13: Total Treatable Population by Type of Treatment of AAA (2021-2034)
Table 14: Total Diagnosed Prevalence of AAA (2021-2034)
Table 15: Total Diagnosed Gender-Specific Prevalence of AAA (2021-2034)
Table 16: Gender-specific Prevalence of AAA (2021-2034)
Table 17: Total Treatable Population of AAA (2021-2034)
Table 18: Total Treatable Population by Type of Treatment of AAA (2021-2034)
Table 19: Total Diagnosed Prevalence of AAA (2021-2034)
Table 20: Total Diagnosed Gender-Specific Prevalence of AAA (2021-2034)
Table 21: Gender-specific Prevalence of AAA (2021-2034)
Table 22: Total Treatable Population of AAA (2021-2034)
Table 23: Total Treatable Population by Type of Treatment of AAA (2021-2034)
Table 24: Total Diagnosed Prevalence of AAA (2021-2034)
Table 25: Total Diagnosed Gender-Specific Prevalence of AAA (2021-2034)
Table 26: Gender-specific Prevalence of AAA (2021-2034)
Table 27: Total Treatable Population of AAA (2021-2034)
Table 28: Total Treatable Population by Type of Treatment of AAA (2021-2034)
Table 29: Total Diagnosed Prevalence of AAA (2021-2034)
Table 30: Total Diagnosed Gender-Specific Prevalence of AAA (2021-2034)
Table 31: Gender-specific Prevalence of AAA (2021-2034)
Table 32: Total Treatable Population of AAA (2021-2034)
Table 33: Total Treatable Population by Type of Treatment of AAA (2021-2034)
Table 34: Total Diagnosed Prevalence of AAA (2021-2034)
Table 35: Total Diagnosed Gender-Specific Prevalence of AAA (2021-2034)
Table 36: Gender-specific Prevalence of AAA (2021-2034)
Table 37: Total Treatable Population of AAA (2021-2034)
Table 38: Total Treatable Population by Type of Treatment of AAA (2021-2034)
Table 39: Total Diagnosed Prevalence of AAA (2021-2034)
Table 40: Total Diagnosed Gender-Specific Prevalence of AAA (2021-2034)
Table 41: Gender-specific Prevalence of AAA (2021-2034)
Table 42: Total Treatable Population of AAA (2021-2034)
Table 43: Total Treatable Population by Type of Treatment of AAA (2021-2034)
List of Figures:
List of Figures
Figure 1: Aortic Aneurysm and Aortic Dissection
Figure 2: Aorta and Bulging Vessel Wall (aneurysm)
Figure 3: Risk Factors of Abdominal Aortic Aneurysm
Figure 4: Non-contrast Axial (A, B) and Coronal (C) CT Images
Figure 5: Axial and Coronal CTA Images of the Abdomen
Figure 6: Axial (A), Coronal (B) and Sagittal (C) Images of the Chest and Abdomen
Figure 7: Axial (A) and Sagittal (B) Images From a CTA Study
Figure 8: Conventional catheter aortogram
Figure 9: Summary of the Pathogenesis of Abdominal Aortic Aneurysm
Figure 10: Diagnosis of Abdominal Aortic Aneurysm
Figure 11: Pathological mechanisms of AAA formation and therapeutic targets for pharmacological agents
Figure 12: Surgical techniques for abdominal aortic aneurysm
Figure 13: Open surgery: The aneurysm is replaced by an artificial vessel (graft)
Figure 14: Endovascular surgery with stent-graft
Figure 15: AAA treatment algorithm
Figure 16: Total Prevalent Population of AAA in 7MM (2021-2034)
Figure 17: Total Gender-specific Prevalent Population of AAA (2021-2034)
Figure 18: Total Size-Specific Prevalence of AAA (2021-2034)
Figure 19: Total Treatable Population of AAA (2021-2034)
Figure 20: Total Treatable Population by Type of Treatment of AAA (2021-2034)
Figure 21: Total Diagnosed Prevalence of AAA (2021-2034)
Figure 22: Total Diagnosed Gender-Specific Prevalence of AAA (2021-2034)
Figure 23: Total Size-Specific Prevalence of AAA (2021-2034)
Figure 24: Total Treatable Population of AAA (2021-2034)
Figure 25: Total Treatable Population by Type of Treatment of AAA (2021-2034)
Figure 26: Total Diagnosed Prevalence of AAA (2021-2034)
Figure 27: Total Diagnosed Gender-Specific Prevalence of AAA (2021-2034)
Figure 28: Total Size-Specific Prevalence of AAA (2021-2034)
Figure 29: Total Treatable Population of AAA (2021-2034)
Figure 30: Total Treatable Population by Type of Treatment of AAA (2021-2034)
Figure 31: Total Diagnosed Prevalence of AAA (2021-2034)
Figure 32: Total Diagnosed Gender-Specific Prevalence of AAA (2021-2034)
Figure 33: Total Size-Specific Prevalence of AAA (2021-2034)
Figure 34: Total Treatable Population of AAA (2021-2034)
Figure 35: Total Treatable Population by Type of Treatment of AAA (2021-2034)
Figure 36: Total Diagnosed Prevalence of AAA (2021-2034)
Figure 37: Total Diagnosed Gender-Specific Prevalence of AAA (2021-2034)
Figure 38: Total Size-Specific Prevalence of AAA (2021-2034)
Figure 39: Total Treatable Population of AAA (2021-2034)
Figure 40: Total Treatable Population by Type of Treatment of AAA (2021-2034)
Figure 41: Total Diagnosed Prevalence of AAA (2021-2034)
Figure 42: Total Diagnosed Gender-Specific Prevalence of AAA (2021-2034)
Figure 43: Total Size-Specific Prevalence of AAA (2021-2034)
Figure 44: Total Treatable Population of AAA (2021-2034)
Figure 45: Total Treatable Population by Type of Treatment of AAA (2021-2034)
Figure 46: Total Diagnosed Prevalence of AAA (2021-2034)
Figure 47: Total Diagnosed Gender-Specific Prevalence of AAA (2021-2034)
Figure 48: Total Size-Specific Prevalence of AAA (2021-2034)
Figure 49: Total Treatable Population of AAA (2021-2034)
Figure 50: Total Treatable Population by Type of Treatment of AAA (2021-2034)
Figure 51: Total Diagnosed Prevalence of AAA (2021-2034)
Figure 52: Total Diagnosed Gender-Specific Prevalence of AAA (2021-2034)
Figure 53: Total Size-Specific Prevalence of AAA (2021-2034)
Figure 54: Total Treatable Population of AAA (2021-2034)
Figure 55: Total Treatable Population by Type of Treatment of AAA (2021-2034)